Rocket One Subsidiary Hoth Therapeutics Ends Phase 2a Trial of HT-001 Early Following Positive Interim Results

Article summary

Hoth Therapeutics, a subsidiary of Rocket One Inc., has decided to conclude its Phase 2a clinical trial for HT-001 early due to strong interim efficacy data and plans to pursue a potential Phase 3 program.